Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gilbert

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 20, 2025
Minimizing and quantifying uncertainty in AI-informed decisions: Applications in medicineSamuel D Curtis, Sambit Panda, Adam Li, et al.
Science Translational Medicine|March 23, 2018
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancersYuxuan Wang, Lu Li, Christopher Douville, et al.
Lancet (London, England)|April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialDomenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 20, 2025
Minimizing and quantifying uncertainty in AI-informed decisions: Applications in medicineSamuel D Curtis, Sambit Panda, Adam Li, et al.
Science Translational Medicine|March 23, 2018
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancersYuxuan Wang, Lu Li, Christopher Douville, et al.
Lancet (London, England)|April 13, 2026
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialDomenica Lorusso, Laurence Gladieff, David M O'Malley, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Pageof 16